EN DE
Watch CytoMed Therapeutics Limited Ordinary Shares for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CytoMed Therapeutics Limited (GDTC) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of CytoMed Therapeutics Limited stock $0.15, price $0.86, that is 82.5% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Singapore · ISIN SGXZ17669631

CT CytoMed Therapeutics Limited logo Thin data Nov 4, 2026

CytoMed Therapeutics Limited

GDTC · US
Very expensive, weak quality

Our calculation puts a fair price 83% below what the stock costs today.

Low debt
Positive coverage
Revenue last quarter 16% below a year ago.
Fair value $0.1500 · Strongly overvalued
Quality 32/100
Weak Growth (revenue 3y −4.4 %/yr in USD)
Negative free cash flow
Trails peers (1/8)
Narrow moat 8/100
Thin data
Watch CytoMed Therapeutics Limited Ordinary Shares for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.64 $0.7230 Fair Value $0.1500 Apr 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

43‑month range $0.7230 – $5.64 · fair‑value band $0.1000 – $0.1800 · the $0.8590 price screens above the $0.1500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow CytoMed Therapeutics Limited Ordinary Shares in your weekly email

Every Wednesday you see whether CytoMed Therapeutics Limited Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

Show moreShow less

The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury.

It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Stock analysis

CytoMed Therapeutics Limited (GDTC) currently trades at $0.8590, while our model-based Fair Value estimate is $0.1500, 83% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 90/100, which puts the data coverage at low.

Scenario range: $0.1000 (bear) to $0.1800 (bull), the price of $0.8590 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CytoMed Therapeutics Limited Ordinary Shares reported revenue of 319K SGD in FY2025 versus 84.2K SGD in FY2021, a compound +39.5%/yr. Reported net income was −3.9M SGD in FY2025.

Key figures

Market cap $10.6M Micro · P/S ratio 14.1 · EPS (TTM) $−0.2500 · Return on equity −56.2% · Return on assets (EBIT) −32.6% (5-year average) · Operating margin −476% · Revenue (TTM) 789K SGD · Revenue growth (YoY) −15.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (medium confidence).

What moves the price

The share trades about 58% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −83%, GDTC screens richer than that median.

Fair Value models

Bear $0.1000 Fair Value $0.1500 Bull $0.1800
Price $0.8590 · Downside -82.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.1000 $0.1500 $0.1800 55
All 1 models by family
Asset-Based
NCAV (Graham) $0.1000 $0.1500 $0.1800 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 8
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 52
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.0%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,955.8% (2020) → −1,416.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GDTC screens overvalued: fair value 83% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (13 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare CytoMed Therapeutics Limited Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −82.5% · Bottom 25%
Profitability
Return on assets −49.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −15.9% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.08× · Pricier than median
P/S (12 months) 17.28× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)97 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs GDTC
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs GDTC
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs GDTC
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs GDTC
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs GDTC
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs GDTC
argenx SE ARGX $927.21 $908.40 −2% vs GDTC
CSL Limited CSL A$200.77 A$183.04 −9% vs GDTC
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs GDTC
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs GDTC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CytoMed Therapeutics Limited Ordinary Shares: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CytoMed Therapeutics Limited Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/GDTC

Frequently asked questions

Is CytoMed Therapeutics Limited (GDTC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.1500 versus a price of $0.8590, about 83% lower (overvalued).
What is the fair value of GDTC?
Our model-based fair value for CytoMed Therapeutics Limited is $0.1500 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.8590.
What is the quality score of GDTC?
CytoMed Therapeutics Limited has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CytoMed Therapeutics Limited (GDTC)?
Our model-based price target is the fair value of $0.1500 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario $0.1000, optimistic scenario $0.1800. It is a calculation from audited fundamentals, not an analyst target.
What is the CytoMed Therapeutics Limited Ordinary Shares stock forecast for 2026?
Our models put fair value at $0.1500, about 83% lower versus a price of $0.8590 (overvalued). Cautious scenario $0.1000, optimistic scenario $0.1800. The calculation is refreshed regularly with new filings.
What is the revenue of CytoMed Therapeutics Limited (GDTC)?
CytoMed Therapeutics Limited reported trailing-twelve-month revenue of about 789K SGD (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of CytoMed Therapeutics Limited (GDTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CytoMed Therapeutics Limited it is $0.1500 per share (as of Nov 4, 2026), against a price of $0.8590. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is CytoMed Therapeutics Limited Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 4, 2026, GDTC trades above its calculated fair value: price $0.8590, fair value $0.1500, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GDTC?
No. The price is what the market pays today ($0.8590); the fair value is what the company's own numbers justify ($0.1500). For CytoMed Therapeutics Limited the two are $0.7090 per share apart. That gap is exactly why we show both numbers side by side.
How much is CytoMed Therapeutics Limited Ordinary Shares worth?
The market values CytoMed Therapeutics Limited at about $10.6M (market capitalisation, as of Nov 4, 2026). Per share that is $0.8590; our models calculate a fair value of $0.1500 per share.
What do the bullish and bearish scenarios say about GDTC?
Our models span a range for CytoMed Therapeutics Limited: cautious scenario $0.1000, base $0.1500, optimistic $0.1800 per share (as of Nov 4, 2026, price $0.8590). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CytoMed Therapeutics Limited (GDTC)?
Balance-sheet figures for CytoMed Therapeutics Limited (as of Nov 4, 2026): return on equity −56.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is GDTC from its 52-week high?
CytoMed Therapeutics Limited trades at $0.8590, about 58% below its 52-week high of $2.04 and 19% above the low of $0.7230 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1500 is for.
Which stocks are comparable to CytoMed Therapeutics Limited Ordinary Shares?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CytoMed Therapeutics Limited Ordinary Shares stock attractive at the current price?
The data as of Nov 4, 2026: price $0.8590, calculated fair value $0.1500 (−83%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GDTC calculated?
We run CytoMed Therapeutics Limited through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.1500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. CytoMed Therapeutics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CytoMed Therapeutics Limited (GDTC)?
The closing price on Nov 6, 2026 was $0.8590. Our model-based fair value is $0.1500, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CytoMed Therapeutics Limited Ordinary Shares right now?
The price sits above even our optimistic bull case ($0.1800). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CytoMed Therapeutics Limited

How large is the market capitalisation of CytoMed Therapeutics Limited (GDTC)?
The market capitalisation of CytoMed Therapeutics Limited is $10.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CytoMed Therapeutics Limited (GDTC)?
The price-to-sales ratio of CytoMed Therapeutics Limited is 14.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CytoMed Therapeutics Limited (GDTC)?
Earnings per share at CytoMed Therapeutics Limited are $−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CytoMed Therapeutics Limited (GDTC)?
The return on equity (ROE) of CytoMed Therapeutics Limited is −56.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CytoMed Therapeutics Limited (GDTC)?
On an EBIT basis the return on assets of CytoMed Therapeutics Limited is −32.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CytoMed Therapeutics Limited (GDTC)?
The operating margin of CytoMed Therapeutics Limited is −476% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CytoMed Therapeutics Limited (GDTC)?
Revenue at CytoMed Therapeutics Limited is growing −15.9% versus a year earlier (3y avg −4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CytoMed Therapeutics Limited (GDTC) generate?
The free cash flow of CytoMed Therapeutics Limited is −4.4M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CytoMed Therapeutics Limited (GDTC) hold?
CytoMed Therapeutics Limited holds more cash than debt, 1.6M SGD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CytoMed Therapeutics Limited Ordinary Shares in the live analysis

One click puts CytoMed Therapeutics Limited Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.